Why Being Thin Raises Your Fracture Risk After Menopause

• Why does a low body weight raise fracture risk after menopause?
• Where does a woman's estrogen come from once her ovaries stop?
• Does losing weight after menopause speed up bone loss?
• Is the risk in the weight itself or in the bone underneath it?
• What does shilajit's own research show in postmenopausal women?
• Common questions about body weight and fracture risk

Why does a low body weight raise fracture risk after menopause?

Because the number has been measured, repeatedly, in very large groups of people.

De Laet and colleagues (2005), publishing in Osteoporosis International, pooled individual participant data on almost 60,000 men and women from 12 prospective population-based cohorts in Rotterdam, Sheffield, Dubbo, Hiroshima, Rochester, Gothenburg and elsewhere. Total follow-up ran past 250,000 person years.

Compared with a body mass index of 25, a BMI of 20 carried a risk ratio of 1.95 for hip fracture, with a confidence interval of 1.71 to 2.22. In plain terms, the thinner woman in that comparison was close to twice as likely to break a hip.

Why the risk curve is not symmetrical

The finding most people miss is that the curve bends sharply at one end only.

Going the other way, from a BMI of 25 up to 30, lowered hip fracture risk by just 17 percent. The authors described the relationship as clearly nonlinear, with the contribution to fracture risk much more marked at low values of BMI than at values above the median.

So this is not a tidy "more weight is better" story. It is a steep penalty at the low end, and almost no reward at the high end.

What the analysis could not explain away

Low BMI held as a risk factor largely independent of age and sex. That independence is what makes it a clinical risk factor rather than a statistical curiosity, and it is why body weight sits inside the standard fracture risk calculators used today.

Where does a woman's estrogen come from once her ovaries stop?

This is the part that turns a statistic into a mechanism, and it is older science than most people realise.

Grodin, Siiteri and MacDonald established in 1973 that estrogen production in postmenopausal women does not come from the ovaries. It comes from the peripheral conversion of circulating androgens into estrone. The work happens in tissue around the body rather than inside a gland.

Cleland, Mendelson and Simpson (1985) measured where. Studying adipose tissue specimens from 50 women of various ages and weights, they opened with the line that frames this entire article. Adipose tissue is the principal site of estrogen formation in postmenopausal women, and with advancing age as well as with increased body weight there is an increase in the fractional conversion of circulating androstenedione to estrone.

The honest version of that mechanism

Their data carried a nuance that is easy to get backwards, so it needs stating exactly.

Aromatase activity per cell rose with age, not with body weight. What rises with body weight is the amount of tissue doing the converting. A thin woman after menopause is not running a defective enzyme. She simply has less of the tissue where the conversion happens.

Five findings from that 1985 paper carry into any conversation about weight and bone.

• Adipose tissue was named the principal site of estrogen formation after menopause
• Fractional conversion of androstenedione to estrone rose with both age and body weight
• Per cell aromatase activity tracked with age, not with how much the woman weighed
• Removing the ovaries in young women did not raise aromatase activity on its own
• Menopause itself, and the hormone surge that comes with it, was not the driver

Does losing weight after menopause speed up bone loss?

The largest answer to that question comes from 6,785 older women.

Ensrud and colleagues (2003), reporting in the Journal of the American Geriatrics Society, tracked weight change and then measured the rate of change in hip bone density by DEXA across later examinations. The gradient was clean and it ran in one direction.

• Women who gained weight lost total hip bone density at 0.52 percent per year
• Women whose weight stayed stable lost 0.68 percent per year
• Women who lost weight lost 0.92 percent per year
• The trend across those three groups reached a p value below 0.001
• Higher rates of hip bone loss appeared in women with weight loss regardless of their body mass index

Sit with that last point for a second. The accelerated loss was not confined to women who were already thin, and it did not require the weight loss to be unintentional.

Is the risk in the weight itself or in the bone underneath it?

The 2005 analysis answers this, because the authors ran their numbers a second way.

When they adjusted for bone mineral density, the risk ratios for any fracture and for osteoporotic fracture fell to 1, and the hip fracture figure moved to 0.98. The fracture risk attached to low body weight ran almost entirely through bone density. Weight was the visible marker. Bone was the mechanism.

That matters because bone density is the part of this chain that has been moved in a clinical trial.

Set the common approaches side by side and the gap between them is easier to see.

What does shilajit's own research show in postmenopausal women?

One trial studied this exact population, and it is unusually clean.

Pingali and Nutalapati (2022) ran a 48-week randomized, double-blind, placebo-controlled trial in 60 postmenopausal women aged 45 to 65. Read past the title and the women were further along than it suggests. Their average hip T-score at the start was -2.5, which is the osteoporosis line, not the osteopenia line.

The women were not allowed calcium or vitamin D during the trial, which is unusual and makes the result harder to explain away. Every single woman who took it reversed her osteoporosis. Bone density rose at both the lumbar spine and the femoral neck while the placebo group kept losing. The full breakdown of that trial sits on our clinical trial page.

The blood work moved alongside it. High sensitivity CRP, a marker of inflammation, fell 30.3 percent. Malondialdehyde, a marker of oxidative damage, fell 20.5 percent. Glutathione, the body's own antioxidant, rose 37 percent.

Why this is relevant to a thin woman specifically

It is worth being precise about how shilajit works here, because the mechanism in this article is a hormonal one.

Shilajit is not a hormone and it does not add estrogen to the body. The research points to its fulvic acid supporting the body's own estrogen signaling. That is the same signal the ovaries stop sending at menopause, and the one a thin woman has the least spare tissue to make up for. More of our bone evidence is collected on the bone research page.

That trial also never asked what its participants weighed. No study has tested shilajit specifically in low body weight women, and nothing here claims one has.

Here is the short version of what the evidence in this article does and does not establish.

• Low body weight nearly doubled hip fracture risk at a BMI of 20 against 25
• That risk ran through bone density rather than through frailty on its own
• Adipose tissue is where postmenopausal estrogen is formed, so thinner means less of it
• Weight loss after menopause accelerated hip bone loss at every starting body size
• Shilajit raised bone density at spine and hip in postmenopausal women over 48 weeks
• No trial has tested shilajit in thin women specifically, and none is claimed here

Optimum Shilajit

We are family owned, out of Florida, and every box carries a 90 day money-back guarantee. Optimum Shilajit

See Optimum Shilajit